Gapping up
In reaction to strong earnings/guidance: TNAV +23.9%, OIIM +23.2%, RGLS +16.1%, NVCR +15.2%, ENPH +13.9%,TTOO +13.8%, (also T2 Biosystems announces a collaboration with Allergan (AGN) to develop a novel diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance; will receive $4 mln in milestone payments ), YELP +11.5%, OCLR+11.3%, CALX +10.4%, CRTO +9.2%, BRCD +8.8%, FLKS +8.5%, IPHI +7%, (Inphi to acquire ClariPhy Communications for $275 million in cash as well as the assumption of certain liabilities at the close), TNET +6.7%, VECO +5.9%, ODP +5.9%,PBPB +5.8%, SQ +5.5%, EA +5%, PZZA +5%, KNOP +5%, WING +4.9%, SHOP +4.7%, TSRA +4.5%, TSRA +4.5%, BGFV+4.1%, NYMT +4%, LNTH +3.9%, HZN +3.6%, BABA +3.6%, NBLX +3.3%, ORBK +3.3%, XCO +2.8%, CYH +2.6%, JIVE+2.5%, ETSY +2.3%, AMSG +2.1%, CIM +2.1%, DVN +1.9%, ELGX +1.8%, BBOX +1.8%, ARCC +1.6%, FNBC +1.5%, TWX+1.4%, TWX +1.4%, CALD +1.2%, NRZ +1.2%, DLPH +1.1%, TRNC +1%, .
M&A news:
In reaction to strong earnings/guidance: TNAV +23.9%, OIIM +23.2%, RGLS +16.1%, NVCR +15.2%, ENPH +13.9%,TTOO +13.8%, (also T2 Biosystems announces a collaboration with Allergan (AGN) to develop a novel diagnostic panel to detect Gram-negative bacterial species and antibiotic resistance; will receive $4 mln in milestone payments ), YELP +11.5%, OCLR+11.3%, CALX +10.4%, CRTO +9.2%, BRCD +8.8%, FLKS +8.5%, IPHI +7%, (Inphi to acquire ClariPhy Communications for $275 million in cash as well as the assumption of certain liabilities at the close), TNET +6.7%, VECO +5.9%, ODP +5.9%,PBPB +5.8%, SQ +5.5%, EA +5%, PZZA +5%, KNOP +5%, WING +4.9%, SHOP +4.7%, TSRA +4.5%, TSRA +4.5%, BGFV+4.1%, NYMT +4%, LNTH +3.9%, HZN +3.6%, BABA +3.6%, NBLX +3.3%, ORBK +3.3%, XCO +2.8%, CYH +2.6%, JIVE+2.5%, ETSY +2.3%, AMSG +2.1%, CIM +2.1%, DVN +1.9%, ELGX +1.8%, BBOX +1.8%, ARCC +1.6%, FNBC +1.5%, TWX+1.4%, TWX +1.4%, CALD +1.2%, NRZ +1.2%, DLPH +1.1%, TRNC +1%, .
M&A news:
- ADGE +20% (to be acquired by Tecogen (TGEN) in a stock-for-stock merger)
- BRCD +9% (Brocade confirms it will be acquired by Broadcom (AVGO) for $12.75 per share)
- CPPL +7.2% (Columbia Pipeline Partners enters into a definitive agreement and plan of merger with TransCanada)
Select optical related names showing strength after OCLR earnings: ACIA +2.2%, FNSR +2.1%, NPTN +2%, .
Select metals/mining stocks trading higher:
Select metals/mining stocks trading higher:
- MUX +3.9%, KGC +3.8%, GOLD +2.8%, FSM +2.7%, SA +2.7%, AUY +2.5%, GDX +2.4%, GG +2.3%, SLW +2.2%, CDE+2.1%, ABX +2%, NEM +1.7%
Other news:
- PTN +38.4% ( reports the Reconnect Studies met the pre-specified co-primary efficacy endpoints in both Phase 3 clinical trials)
- AVXS +20.8% (provides update after receipt of FDA minutes from Type B meeting; AVXS-101 study will reflect a single-arm design, using natural history of the disease as a comparator, and enroll approximately 20 patient)
- CXRX +7.7% (enters into an additional cross currency swap agreement as part of its ongoing currency hedging program)
- IPAS +7.3% (extends partnership w/ Gogo )
- HLS +5.7% (HealthSouth (HLS) will replace Rackspace Hosting (RAX) in the S&P Midcap 400 after the close of trading on November 3)
- JBSS +4.1% (declares a special cash dividend of $2.50/share )
- INFI +2.4% (enters into a license agreement under which Verastem (VSTM) licensed worldwide rights to develop/commercialize its duvelisib)
- YHOO +2.2% (in sympathy with BABA earnings)
- ATVI +2.1% (following EA earnings/guidance)
- OMER +2% (announces results from a Phase 2 trial evaluating peroxisome proliferator-activated receptor-gamma agonist in heroin-dependent subject)
- AVH +1.6% (following late move higher on reports that UAL / DAL nearing bid)
- URRE +1.6% (announces expansion of its claim position at the Sal Rica Lithium Brine project in Utah)
- FINL +1.5% (on late report that the company could divest its Jackrabbit unit)
- TSRO +1.5% (announces that it has completed the niraparib rolling New Drug Application submission to the FDA for the maintenance treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy)
Analyst comments:
- AMSG +2.1% (upgraded to Outperform from Market Perform at Wells Fargo)